Dyslipidemia: What You Need to Know

We have talked about the comorbidities of high visceral fat and insulin resistance; well, dyslipidemia is one of them. What you need to know about dyslipidemia is that it is a condition linked to abnormally high concentration of lipids in the blood. It is considered one of the main risk factors for the development of cardiovascular disease (CVD).

ACC/ AHA treatment guidelines

The diagnosis of dyslipidemia in adult patients comes after a complete assessment of the blood’s lipid concentration. It should be followed by an advanced anthropometric analysis, clinical medical history, and lifestyle habits. Consequently, the standard of care takes the following markers as part of the risk assessment procedure.

We have talked about the comorbidities of high visceral fat and insulin resistance; well, dyslipidemia is one of them. What you need to know about dyslipidemia is that it is a condition linked to abnormally high concentration of lipids in the blood. It is considered one of the main risk factors for the development of cardiovascular disease (CVD).

ACC/ AHA treatment guidelines

The diagnosis of dyslipidemia in adult patients comes after a complete assessment of the blood’s lipid concentration. It should be followed by an advanced anthropometric analysis, clinical medical history, and lifestyle habits. Consequently, the standard of care takes the following markers as part of the risk assessment procedure.

In addition to these markers, this approach recommends taking a personalized point of view by measuring Lipoprotein (a) (<50mg/dL) and Apolipoprotein B (>120mg/dL). Also, taking into account the patient’s ethnicity, family history of premature ASCVD, antecedents of chronic inflammatory disorders, metabolic syndrome, chronic kidney disease, preeclampsia or premature menopause in women, and proinflammatory markers such as Hs- CRP <2.0mg/L. This criterion allows improved risk prevention and has a patient-focused approach.

Nowadays, clinical practice guidelines assure that the best way to treat this condition is by assessing the risk factor that might affect the patient. In fact, the guideline of the management of blood cholesterol of the American College of Cardiology and American Heart Association published in 2018 states the next:

“In all individuals, emphasize a heart-healthy lifestyle across the life course. A healthy lifestyle reduces atherosclerotic cardiovascular disease (ASCVD) risk at all ages. In all age groups, lifestyle therapy is the primary intervention for metabolic syndrome.”

Therefore, this statement sends a direct message; prevention is the first and most important treatment you can provide to your patient. Indeed, this same statement is number one of the top 10 take-home messages to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). Also, the standard of care and the clinical guidelines are considering a much broader angle to treat this condition.

The contributions of the standard of care are outstanding and should be followed. However, personalized treatment, assessment, and lifestyle modifications should always be considered in the clinical guidelines. In fact, ACC/AHA mentions lifestyle modification but does not state how to introduce those changes into the treatment. Instead, the information focuses on the pharmacological treatment with statins.

Treatment with statins represents a challenge since they come with secondary effects linked to lower quality of life (QOL).

Mediterranean diet and dyslipidemia.

What do we need to know about lifestyle changes to lower dyslipidemia? Diet pattern modification is an excellent example of how food is medicine. Functional Medicine’s personalized approach is evidence-based. Mediterranean diet interventions have positively impacted the lipid profile, protect against oxidative stress, inflammation, and platelet aggregation, and promote gut microbiota-mediated production of metabolites influencing metabolic health.

Epidemiological evidence:

 

The adherence to the Mediterranean diet (MD) is associated with protective effects against cardiovascular disease, stroke, obesity, diabetes, hypertension, several types of cancers, allergic diseases, and, most recently, Alzheimer’s and Parkinson’s disease.

• In an epidemiological study involving 22,304 men and women, MD showed a lower total cardiac mortality.
• In another study of 2,339 men and women aged 70- 90 y/o, adherence to MD was linked to a 23% or a lower rate of all-cause mortality.
• In the Lyon Diet Heart Study, involving 605 men and women who had suffered prior myocardial infraction were assigned into two groups, the American Heart Association step 1 diet or a diet resembling MD, supplemented with ALA margarine. After a 27-month intervention, the MD group showed a significant 70% reduction in all-cause mortality due to a 73% reduction in coronary heart disease mortality and major reductions in nonfatal complications.
• An “Indo-Mediterranean diet” study was conducted in 1000 Indian patients with high risk or existing coronary heart disease. The MD group was compared to a step 1 National Cholesterol Education program diet. Furthermore, the study resulted in an approximate 50% reduction in nonfatal myocardial infarction and an approximate 60% reduction in the rate of sudden cardiac death in the “Indo-Mediterranean diet” group.
• The PRIDIMED study supplemented the MD with approximately 1liter per week of extra-virgin olive oil or 30g of mixed nuts. This study was conducted on 7.447 men and women at high cardiometabolic risk. Furthermore, after a follow-up of 4.8 years, the absolute risk reduction was about three major cardiovascular events per 1,000 person-years, for a relative risk reduction of approximately 30%.
• Sub-studies from PRIDIMED authors resulted in reducing peripheral artery disease, atrial fibrillation, breast cancer, and type 2 diabetes.

Evidence-based medicine and clinical guidelines are blueprints to follow by clinicians when they are applying their critical thinking. However, the pharmacological approach needs extra help to acquire the patient’s needs. All of the time, care providers are looked upon like healers, and it’s our job to meet the requirements. By looking outside of the prescription pad, we can be able to visualize a personalized treatment.

I am the daughter of an Internist. I had the pleasure of working along with my dad as his nutritionist. I have seen many patients improve their lipid profile with statins, a personalized diet, and exercise inclusion (the hardest part of the treatment). However, they never come to me for the side effects since erectile dysfunction is a topic our patients prefer to talk about with my dad. Most of the time, my dad prescribes a statin for a three-month period. This allows the patient to deal daily with the lifestyle changes while providing the sense of security and health that comes with the lower lipid concentration in the lab work. Ultimately, the promise is that the patient would keep low lipid concentration without the pill if they can adhere to the dietary and exercise adjustments. My dad and I can say that an integrative care plan results in better outcomes. – Ana Paola Rodríguez Arciniega, MS

References

 

Kozlik, Hayley J., Athena Hathaway Meskimen, and Beatrice Alexandra Golomb. “Physicians’ experiences as patients with statin side effects: a case series.” Drug safety-case reports 4.1 (2017): 3.

Stein, Ricardo, Filipe Ferrari, and Fernando Scolari. “Genetics, dyslipidemia, and cardiovascular disease: new insights.” Current cardiology reports 21.8 (2019): 1-12.

Grundy, Scott M, et al. “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Journal of the American College of Cardiology vol. 73,24 (2019): 3168-3209. doi:10.1016/j.jacc.2018.11.002

Tosti, Valeria et al. “Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms.” The journals of gerontology. Series A, Biological sciences and medical sciences vol. 73,3 (2018): 318-326. doi:10.1093/Gerona/glx227

Additional Online Links & Resources (Available 24/7)



Online Appointments or Consultations:  bit.ly/Book-Online-Appointment

Online Physical Injury / Accident Intake Form: bit.ly/Fill-Out-Your-Online-History

Online Functional Medicine Assessment: bit.ly/functionmed

Disclaimer

The information herein is not intended to replace a one-on-one relationship with a qualified health care professional, licensed physician, and not medical advice. We encourage you to make your own health care decisions based on your research and partnership with a qualified health care professional. Our information scope is limited to chiropractic, musculoskeletal, physical medicines, wellness, sensitive health issues, functional medicine articles, topics, and discussions. We provide and present clinical collaboration with specialists from a wide array of disciplines. Each specialist is governed by their professional scope of practice and their jurisdiction of licensure. We use functional health & wellness protocols to treat and support care for the musculoskeletal system’s injuries or disorders. Our videos, posts, topics, subjects, and insights cover clinical matters, issues, and topics that relate to and support, directly or indirectly, our clinical scope of practice.* Our office has made a reasonable attempt to provide supportive citations and has identified the relevant research study or studies supporting our posts. We provide copies of supporting research studies available to regulatory boards and the public upon request. We understand that we cover matters that require an additional explanation of how it may assist in a particular care plan or treatment protocol; therefore, to further discuss the subject matter above, please feel free to ask Dr. Alex Jimenez or contact us 915-850-0900.  Read More…

Dr. Alex Jimenez DC, MSACP, CCST, IFMCP*, CIFM*, CTG*

email: coach@elpasofunctionalmedicine.com
phone: 915-850-0900
Licensed in Texas & New Mexico